Caroline Papeix

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults

Álvaro Cobo‐Calvo, Anne Ruiz, Élisabeth Maillart et al. · Neurology · 2018 · 508 citations · Full text

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis

Céline Louapre, Nicolas Collongues, Bruno Stankoff et al. · JAMA Neurology · 2020 · 461 citations · Full text

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

Ayman Tourbah, Christine Lebrun‐Frénay, Gilles Edan et al. · Multiple Sclerosis Journal · 2016 · 284 citations · Full text

Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Álvaro Cobo‐Calvo, Anne Ruiz, Fabien Rollot et al. · Annals of Neurology · 2020 · 242 citations · Full text